The U.S. Food and Drug Administration has approved Xenpozyme (olipudase alfa) for pediatric and adult patients with acid sphingomyelinase deficiency (ASMD), a rare genetic disease.
This article was originally published on MedicalXpress.com
FDA approves first treatment for acid sphingomyelinase deficiency
You may also be interested in:
The Latest
How metacognition — thinking about thinking — can improve the mental-health crisis
In these times of virtual meet-ups, negative news overload and widespread uncertainty, it’s fair to say it has been a tough time for our brains. If you’ve been feeling mentally subpar, you may be floating […]
The Latest
Will a nutritional supplement help you run better?
Whether you jog to keep fit or compete in marathons, the physically demanding sport of running can deplete the body of essential nutrients. During a race like a half-marathon, a runner’s metabolism — or ability […]
The Latest
Lyme carditis: Things can get complicated when Lyme disease affects heart function
Lyme disease is a tick-born infection caused by bacteria known as Borrelia burgdorferi. Lyme carditis is an early manifestation of Lyme disease that can occur two to six weeks after the tick bite. Approximately five to 10 per […]
Read More:
-
Researchers are joining forces with the food and health industries to tighten controls and improve nutrition for infants and children.This article was originally published on [...]
-
Toddlers whose moms were exposed to higher levels of air pollution during mid- to late-pregnancy tend to score lower on measures of cognition, motor coordination [...]
-
When visiting friends or family who have both houseplants and young children, I’ve been compared to “Aunt Bonnie” from the Geico commercial “Aunt Infestation.”This article [...]
